Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

OBJECTIVE: To date, there are no predictive biomarkers to guide selection of patients with gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional group Trial (SAMIT) was a 2×2 factorial randomised phase III study in which patients with GC were randomised to Pac-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundar, Raghav, Barr Kumarakulasinghe, Nesaretnam, Huak Chan, Yiong, Yoshida, Kazuhiro, Yoshikawa, Takaki, Miyagi, Yohei, Rino, Yasushi, Masuda, Munetaka, Guan, Jia, Sakamoto, Junichi, Tanaka, Shiro, Tan, Angie Lay-Keng, Hoppe, Michal Marek, Jeyasekharan, Anand D., Ng, Cedric Chuan Young, De Simone, Mark, Grabsch, Heike I., Lee, Jeeyun, Oshima, Takashi, Tsuburaya, Akira, Tan, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Stomach
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921574/
https://www.ncbi.nlm.nih.gov/pubmed/33980610
http://dx.doi.org/10.1136/gutjnl-2021-324060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921574/
https://www.ncbi.nlm.nih.gov/pubmed/33980610
http://dx.doi.org/10.1136/gutjnl-2021-324060

Ejemplares similares